As atrial fibrillation quietly becomes one of the defining cardiac challenges of our era, a Norwegian trial has offered something rare in medicine: a practical, scalable answer. The NEXAF study demonstrated that a structured exercise program—beginning with supervised intensity and sustained through digital tools—reduced the burden of irregular heart rhythm by nearly half among 295 patients over a year. The findings arrive at a moment when European guidelines already endorse such rehabilitation, yet fewer than one in ten eligible patients ever receive it, raising the enduring question of how lo
Exercise Program Cuts Atrial Fibrillation Burden by 45% in Major Trial
A 45% reduction in atrial fibrillation burden, fewer hospital admissions
Mark
So the exercise program cut atrial fibrillation burden nearly in half. That's a big number. What does "burden" actually mean here?
Mimi
It's the percentage of time the heart is in an irregular rhythm. The exercise group went from 7.1 percent of their monitored time in AF down to 3.9 percent. That's real time the heart spent beating normally.
Luke
But we should note—that's a relative reduction of 45 percent, which sounds bigger than the absolute difference. The actual drop was 3.2 percentage points. Still meaningful, but the framing matters.
Mimi
Fair. And the hospitalization reductions were substantial too—37 percent fewer total admissions, 46 percent fewer AF-related ones.
Mark
Did the program actually make people feel better? That seems like it would matter.
Mimi
That's where it gets complicated. Quality of life scores improved in both groups, but there was no statistically significant difference between them. The exercise group gained 5.6 points on the AFEQT scale, usual care gained 4.4.
Luke
Which means we can't say the exercise program improved quality of life compared to usual care. Both groups got better, possibly from being monitored, possibly from natural variation.
Mark
So fewer arrhythmias, fewer hospitalizations, but not necessarily feeling better?
Mimi
The reduction in hospitalizations is itself a form of feeling better—fewer emergency visits, less disruption. But you're right that the subjective experience didn't show a clear advantage.
Mark
How many people were in this trial?
Luke
295 total, split evenly between exercise and usual care. Mean age 64, 30 percent women. That's a reasonable size for this kind of study.
Mark
And the exercise part—was it something people could actually stick with?
Mimi
Eight supervised sessions in the first month and a half, then home-based work with digital support. They used smartwatches and apps. The researchers said it was feasible with modest resources, which suggests it could scale.
Luke
Though we don't have data on adherence rates or dropout. We know the intervention was delivered, but not how many people stuck with it or how well.
Mark
What's the bigger picture here?
Mimi
There's a huge gap between what guidelines say and what actually happens. Only about 1 in 10 eligible AF patients get referred to exercise programs, even though the evidence supports it.
Luke
And now there's better evidence. This trial was longer and more rigorous than most prior work, with continuous monitoring. That strengthens the case for implementation.
El Pulso
- Atrial fibrillation is rising even as other heart diseases retreat, and most patients are left without structured exercise support despite guidelines calling for it.
- The NEXAF trial found that a hybrid program—eight supervised high-intensity sessions followed by smartwatch and app-guided home exercise—cut AF burden from 7.1% to 3.9% of monitored time, a 45% relative reduction.
- Hospital admissions fell by 37% overall and by 46% for AF-specific stays, signaling that the intervention's benefits extend well beyond rhythm metrics into real-world healthcare costs and patient suffering.
- Quality-of-life scores improved in both groups but did not differ significantly between them, leaving one important dimension of benefit still unresolved.
- With the ESC simultaneously releasing its first dedicated cardiac rehabilitation guidelines, the trial's findings land in a system where the implementation gap—not the evidence gap—has become the central problem.
As atrial fibrillation quietly becomes one of the defining cardiac challenges of our era, a Norwegian trial has offered something rare in medicine: a practical, scalable answer. The NEXAF study demonstrated that a structured exercise program—beginning with supervised intensity and sustained through digital tools—reduced the burden of irregular heart rhythm by nearly half among 295 patients over a year. The findings arrive at a moment when European guidelines already endorse such rehabilitation, yet fewer than one in ten eligible patients ever receive it, raising the enduring question of how long evidence must wait before it becomes care.
Atrial fibrillation is growing more common even as other heart conditions stabilize, yet most patients with the condition are never referred to structured exercise programs despite clear guideline recommendations. The NEXAF trial, presented at the 2026 European Society of Cardiology Congress, set out to test whether a carefully designed, resource-modest intervention could change that reality.
Led by Dr. Bjarne Nes at the Norwegian University of Science and Technology, the trial enrolled 295 patients with non-permanent atrial fibrillation who were not meeting standard physical activity guidelines. Averaging 64 years old, they were randomly assigned to either a one-year exercise program or standard care. All received an implantable cardiac monitor to continuously track heart rhythm throughout the study.
The program was built for practicality: eight supervised high-intensity sessions in the first four to six weeks, then a transition to home-based exercise guided by smartwatch, mobile app, and web platform. The hybrid model required modest staffing and proved clinically feasible to deliver at scale.
The results were clinically meaningful. AF burden dropped to 3.9% of monitored time in the exercise group versus 7.1% in usual care—a 45% relative reduction. Cardiorespiratory fitness improved, resting heart rate fell, and hospital admissions declined by 37% overall and 46% for AF-related stays. One measure fell short: quality-of-life scores improved in both groups, but the difference between them did not reach statistical significance.
Dr. Nes framed the trial as a direct response to a persistent gap—European guidelines already recommend exercise rehabilitation for AF patients, yet only about one in ten eligible individuals are ever referred. The NEXAF findings, backed by continuous rhythm monitoring and a full year of follow-up, provide the rigorous long-term evidence that prior small, short-term studies could not. As the ESC publishes its first dedicated cardiac rehabilitation guidelines, the question is no longer whether exercise helps—it is whether health systems will finally act on what the evidence has been saying.
Atrial fibrillation is becoming more common even as other heart conditions stabilize or decline. The condition disrupts the heart's rhythm, and while doctors know that exercise and lifestyle changes help manage it, most patients never get referred to structured programs. At the European Society of Cardiology Congress in 2026, researchers presented evidence that a carefully designed exercise intervention could change that picture significantly.
The NEXAF trial, led by Dr. Bjarne Nes at the Norwegian University of Science and Technology, enrolled 295 patients with non-permanent atrial fibrillation who were not meeting standard physical activity guidelines. The patients averaged 64 years old; 30 percent were women. Researchers randomly assigned them to either a one-year exercise program or standard care with no structured exercise component. All participants received an implantable cardiac monitor to track their heart rhythm continuously throughout the year.
The exercise program itself was designed to be practical. Patients attended eight high-intensity supervised sessions over the first four to six weeks, then transitioned to home-based exercise guided remotely through a smartwatch, a mobile app, and a web platform. This hybrid approach—intensive upfront, then sustained through digital tools—required modest staffing and proved clinically feasible to deliver.
The results were substantial. Patients in the exercise group saw their atrial fibrillation burden drop to 3.9 percent of monitored time, compared to 7.1 percent in the usual care group—a 45 percent relative reduction. Beyond that primary measure, the exercise intervention improved cardiorespiratory fitness and lowered resting heart rate. Hospital admissions fell by 37 percent overall and by 46 percent specifically for atrial fibrillation-related stays. These were not marginal gains; they represented meaningful clinical improvements that would reduce both patient suffering and healthcare costs.
One finding did not reach statistical significance: quality of life scores improved modestly in both groups, with no clear advantage for the exercise intervention. The AFEQT questionnaire, which measures how atrial fibrillation affects daily functioning, showed gains of 5.6 points in the exercise group versus 4.4 in usual care—a difference that could reflect chance rather than true benefit.
Dr. Nes emphasized that the trial addressed a real gap in current practice. European guidelines recommend exercise-based rehabilitation for atrial fibrillation patients, yet only about one in ten eligible people are actually referred for it. Most prior studies on exercise and atrial fibrillation were small, short-term, and did not continuously monitor heart rhythm the way this trial did. The NEXAF results provide the kind of rigorous, long-term evidence that could justify broader implementation.
The findings arrive as the European Society of Cardiology has just published its first dedicated guidelines on cardiac rehabilitation. For atrial fibrillation patients, the message is clear: structured exercise, delivered through a combination of supervised sessions and remote monitoring, can substantially reduce the burden of the condition. The question now is whether health systems will act on that evidence and close the gap between what guidelines recommend and what patients actually receive.
Citas Notables
In this large, randomized trial, a one-year exercise intervention induced a meaningful reduction in total AF burden, improved fitness and led to fewer AF-related hospital admissions compared to usual care.— Dr. Bjarne Nes, Principal Investigator, NEXAF trial
The hybrid model combining short-term supervision with long-term home-based exercise and digital support was delivered with modest personnel resources and was clinically feasible.— Dr. Bjarne Nes
Quieres la nota completa?
Lee el original en News-Medical ↗
Health & Medicine